期刊文献+

早期妊娠妇女凝血、抗凝、纤溶与抗纤溶指标的测定 被引量:2

Indexes determination of coagulation, anticoagulation, fibrinolysis and antifibrinolytic in early pregnancy
原文传递
导出
摘要 目的了解早期妊娠凝血、抗凝、血栓形成、纤溶和抗纤溶状态的改变。方法选取105例妊娠10~12周孕妇为研究组,另选取82例正常未孕者为对照组。测定凝血状态指标,包括凝血常规即血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(Fg)以及凝血酶原片段1+2(F1+2)、凝血酶-抗凝血酶复合物(TAT),同时测定抗凝、纤溶与抗纤溶分子标志物,包括抗凝血酶-Ⅲ(AT-Ⅲ)、血小板颗粒糖蛋白140(GMP140)、血栓烷B2(TXB2)、D二聚体(D-Ⅱ)、纤溶酶原激活物抑制物(PAI-2)。结果研究组Fg、F1+2、TAT、D-Ⅱ、PAI-2分别为4.00、179.95、0.66、201.51、46.80,明显高于对照组的2.52、39.46、0.31、125.02、5.87,差异有统计学意义(P<0.008),而研究组反映血栓形成的指标GMP140为9.42,显著低于对照组的19.13,差异有统计学意义(P<0.008)。结论正常妊娠早期,血液凝血功能增强,抗凝状况无明显改变,纤溶活性及抗纤溶活性出现亢进,血栓形成减少,这样的改变可能有利于保持充足的胎盘子宫血流灌注量。 Objective To explore the changes in coagulation, anticoagulation, fibrinolysis and antifibrinolytic during early pregnancy. Methods 105 pregnant women who conceived from 10 to 12 weeks were enrolled as the study group, and 82 non- pregnant women were selected as the control group. Coagulation, anticoagulation, fibrinolysis and antifibrinolytic parameters were measured. Results Fg, Fl+2, TAT, GMP140, D-dimer and PAI-2 in the study group were statistically different to the control group (P〈0.008). Conclusion The coagulation, fibrinolytic, and the antifibrinolytic functions of healthy pregnant women are enhanced during early pregnancy. Such changes may help maintaining adequate placental uterine blood flow perfusion.
出处 《热带医学杂志》 CAS 2013年第3期313-315,331,共4页 Journal of Tropical Medicine
基金 国家自然科学基金(81270754 81170625 81000259) 东省自然科学基金(10451008901004246) 教育部博士点新教师基金(20090171120075) 广东省科技计划项目(2012B031800352 2011B031800119 2010B060900034 2009B030801157) 广东省医学科研基金(A2010171) 中山大学5010计划(2012006) 中山大学青年教师培育项目(12ykpy29)
关键词 早期妊娠 活化部分凝血活酶时间 纤维蛋白原 血小板颗粒糖蛋白140 early pregnant activated partialthromboplastin time fibrinogen granule membrane glycoprotein of platelet
  • 相关文献

参考文献7

二级参考文献33

  • 1杨进.足月妊娠妇女血浆凝血因子活性的观察[J].第一军医大学学报,1993,13(3):288-288.
  • 2[5]Peerschke EIB. Recognition of platelet-associated fibrinogen by ploy-clonal antibodies: correlation with platelet aggregation. Blood, 1992,79: 20 ~ 28.
  • 3Ramalakshmi BA,Raju LA,Raman L.Antithrombin III levels in pregnancy induced hypertension [ J ].Natl Med J India, 1995,8 ( 2 ) : 61-62.
  • 4Benedetto C, Marozio L, Salton L, et al.Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome [J].Acta Obstet Gynecol Scand, 2002,81 (12) : 1095-1100.
  • 5Kosmas IP,Tatsioni A,Ioannidis JPA.Association of Leiden mutation in Factor V gene with hypertension in pregnancy and pre- eclampsia: a meta-anaIysis [J].J Hypertens,2003,21 (7) : 1221-1228.
  • 6Davalos IP, Moran MC, Martlnez-Abundis E, et al.Methylenete- trahydrofolate reductase C677T polymorphism and Factor V Leiden variant in Mexican women with preeclampsia/eclampsia [J]. Blood Cells Mol Dis, 2005,35 ( 1 ) : 66-69.
  • 7Hirsh J, Weitz JI.Thrombosis and anticoagulation [ J ] .Semin Hematol, 1999,36(4S 7): 118-132.
  • 8Nurk E,Tell GS,Refsum H,et al.Factor V Leiden,pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study [ J ].QJM, 2006,99 (5) : 289-298.
  • 9Hiltunen LM, Laivuori H, Rautanen A, et al.Blood group AB and factor V Leiden as risk factors for pre-eelampsia:A populationbased nested case-control study[J]. Thromb Res,2009,124 (2): 167-173.
  • 10Kobashi G,Yamada H,Asano T,et al.The factor V Leiden mutation is not a common cause of pregnancy-induced hypertension in Japan [JJ. Semin Thromb Hemost, 1999,25 (5): 487-489.

共引文献186

同被引文献18

引证文献2

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部